Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells $51,204.24 in Stock

Posted by George Bondi on Jun 18th, 2026

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CEO Quang Pham sold 12,996 shares of the stock in a transaction on Friday, June 12th. The shares were sold at an average price of $3.94, for a total value of $51,204.24. Following the completion of the sale, the chief executive officer directly owned 136,381 shares of the company’s stock, valued at $537,341.14. The trade was a 8.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Cadrenal Therapeutics Trading Up 2.0%

NASDAQ CVKD opened at $3.10 on Thursday. The firm has a market capitalization of $8.90 million, a P/E ratio of -0.55 and a beta of 1.59. The business has a fifty day simple moving average of $4.95 and a 200 day simple moving average of $6.50. Cadrenal Therapeutics, Inc. has a 12 month low of $3.02 and a 12 month high of $14.64.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, beating the consensus estimate of ($1.51) by $0.47. As a group, sell-side analysts predict that Cadrenal Therapeutics, Inc. will post -5.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Cadrenal Therapeutics

Several large investors have recently modified their holdings of CVKD. Geode Capital Management LLC increased its holdings in Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after acquiring an additional 1,818 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Cadrenal Therapeutics in the 3rd quarter worth about $103,000. Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics in the 3rd quarter worth about $274,000. Finally, DRW Securities LLC purchased a new stake in Cadrenal Therapeutics in the 4th quarter worth about $171,000. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wall Street Zen upgraded shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Monday, April 20th. Finally, HC Wainwright decreased their target price on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $13.00.

View Our Latest Analysis on CVKD

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.